List view / Grid view
23 May 2006 | By Dominique Perrin, Alexander Scheer and Timothy N.C. Wells, Serono Pharmaceutical Research Institute
There has been a sea change in the way many biotech and pharma companies view the search for new drugs in neglected disease. Serono is a biotech company, with interests in neurology, reproductive health, oncology and dermatology – but we teamed up with the World Health Organization (WHO) to train…
2 February 2006 | By Quan Du, Institute of Molecular Medicine, Peking University, Meihong Chen, Chinese Human Genome Center Beijing, Claes Wahlestedt, Scripps Florida and Zicai Liang, Karolinska Institute
Although synthetic siRNA libraries are becoming more available, most high throughput siRNA library-based screening was carried out with siRNA libraries encoded by different vectors. In this article, siRNA library construction methods and HTS applications are summarised.
2 February 2006 | By Elisabeth Pook, Stefan Martin Mundt, Adrian Tersteegen, Department of Cardiovascular Research, Pharma Research Center Wuppertal, Bayer HealthCare AG
Ultra high-throughput screening (UHTS) offers the possibility to discover novel pharmacophores. To benefit from UHTS special demands concerning assay quality and data analysis have to be met.
22 August 2005 | By Dr Johannes Ottl, Laboratory Head, Novartis Pharmaceuticals
The pharmaceutical industry continues to face an ever-changing, increasingly competitive business environment. This makes it imperative for drug discovery and development efforts to incorporate new technologies in order to reduce time-to-market to survive in today’s competitive marketplace. This industry pressure to shorten the R&D process has seen high-throughput screening (HTS)…
20 May 2005 | By Peter Hodder, Ph.D., Director & Head of Lead ID, Scripps Florida
In pharmaceutical drug discovery research, several technological advances have moved in vitro biological and biochemical experiments from the laboratory benchtop to fully automated high-throughput screening (HTS) robotic platforms1,2.
7 March 2005 | By Oliver Bruttger, Danielle Folio, Christine Niklaus and Johannes Ottl, Novartis Institute for BioMedical Research, Lead Discovery Center Basel
Research and development for a pharmaceutical company is a difficult and lengthy process. It stretches from the discovery phase to preclinical and clinical development stage, through the drug approval period ultimately to clinical application. The discovery research phase is one of the early key processes. The research starts with target…
